Anti-CD19 and anti-BCMA CAR T cell therapy followed by lenalidomide maintenance after autologous stem-cell transplantation for high-risk newly diagnosed multiple myeloma

Shi, XL; Yan, LZ; Shang, JJ; Kang, LQ; Yan, Z; Jin, S; Zhu, MQ; Chang, HR; Gong, FR; Zhou, JZ; Chen, GH; Pan, JL; Liu, DD; Zhu, XM; Tang, F; Liu, MH; Liu, W; Yao, FR; Yu, L; Wu, DP; Fu, CC

Wu, DP; Fu, CC (通讯作者)，Soochow Univ, Jiangsu Inst Hematol, Natl Clin Res Ctr Hematol Dis, Affiliated Hosp 1, 188 Shizi St, Suzhou, Peoples R China.;Yu, L (通讯作者)，Shanghai Unicar Therapy Bio Med Technol Co Ltd, Bldg 2,1525 Minqiang Rd, Shanghai, Peoples R China.

AMERICAN JOURNAL OF HEMATOLOGY, 2022; 97 (5): 537

Abstract

Few prospective studies have examined posttransplant chimeric antigen receptor (CAR) T cell infusion as candidates for front-line consolidation therap......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索